Angiotensin II
- Generic Name
- Angiotensin II
- Brand Names
- Giapreza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 4474-91-3
- Unique Ingredient Identifier
- M089EFU921
- Background
Angiotensin II is under investigation for the treatment of Sepsis, Septic Shock, Diabetes Mellitus, and Acute Renal Failure. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy.
...
- Indication
Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock .
- Associated Conditions
- Hypotension
- Associated Therapies
- -
Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- Universität Münster
- Target Recruit Count
- 1022
- Registration Number
- NCT06615102
ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)
- Conditions
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- University of Maryland St. Joseph Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT06487585
The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock
- Conditions
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 45
- Registration Number
- NCT06234592
- Locations
- 🇬🇧
King's College Hospital, London, United Kingdom
Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Anna Stanhewicz, PhD
- Target Recruit Count
- 30
- Registration Number
- NCT06157580
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 40
- Registration Number
- NCT05824767
- Locations
- 🇺🇸
University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
Reducing Acute Kidney Injury Occurence by Administering Angiotensin II
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Universität Münster
- Target Recruit Count
- 64
- Registration Number
- NCT05199493
- Locations
- 🇩🇪
University Hospital Muenster, Münster, Germany
Angiotensin II vs. Vasopressin in Septic Shock
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- University of New Mexico
- Registration Number
- NCT05193370
- Locations
- 🇺🇸
University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
Angiotensin II for Distributive Shock
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 40
- Registration Number
- NCT04904562
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Angiotensin II in Liver Transplantation
- Conditions
- Interventions
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 50
- Registration Number
- NCT04901169
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Angiotensin 2 for AKI After OLT
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 30
- Registration Number
- NCT04592744
- Locations
- 🇺🇸
Michael Y Lin, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.